Related Experiment Video
Updated: Feb 20, 2026
06:32
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
8.3K
SEOM clinical guidelines for anaplastic gliomas (2017)
C Balañá1, M Alonso2, A Hernandez-Lain
1Institut Català Oncologia Badalona, Ct. Canyet, s/n, 08916, Barcelona, Spain. cbalana@iconcologia.net.
Summary
These clinical guidelines offer recommendations for diagnosing and treating adult anaplastic gliomas (AG), incorporating molecular markers like IDH1/IDH2 mutations and 1p/19q codeletions for personalized care.
Area of Science:
- Neuro-oncology
- Clinical guidelines
- Molecular diagnostics
Background:
- Anaplastic gliomas (AG) require standardized management protocols.
- The 2016 WHO classification highlights the importance of molecular markers in glioma diagnosis.
- Previous guidelines may not fully integrate the latest molecular insights.
Purpose of the Study:
- To provide updated clinical recommendations for the diagnosis, treatment, and follow-up of adult anaplastic gliomas.
- To integrate radiological and molecular findings into a unified management strategy.
- To emphasize the prognostic and predictive value of IDH1/IDH2 mutations and 1p/19q codeletions.
Main Methods:
- Adherence to the 2016 WHO classification for glioma diagnosis.
- Review and synthesis of current evidence for treatment modalities.
- Incorporation of molecular diagnostic criteria (IDH1/IDH2, 1p/19q codeletion).
Main Results:
- Recommendations cover radiological and molecular diagnosis, surgery, radiotherapy, and chemotherapy (PCV or TMZ).
- The diagnosis of anaplastic oligoastrocytoma is discouraged.
- Treatment strategies are tailored based on molecular variables.
Conclusions:
- Multidisciplinary team management is highly recommended for optimal patient outcomes.
- Updated guidelines facilitate personalized treatment approaches for anaplastic gliomas.
- Molecular profiling is integral to the modern management of AG.
